Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is trading at $31.64, about ₹3,039 at today's USD/INR rate, as of 29 Sep 2026, 4:00 PM ET, up 0.48% today. Indian residents can buy Celldex Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$31.00
Today's high
$31.79
52 week low
$22.10
52 week high
$45.14
CLDX opened at $31.49, closed previously at $31.49, and has traded between $22.10 and $45.14 over the past 52 weeks.
About
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Key statistics
Avg. volume
1.17M
Market cap
$2.11B
P/E Ratio
-7.26
Price-to-sales ratio
18797.12
Enterprise value
$1.78B
Free cash flow yield
-11.83%
Debt-to-equity ratio
0.01
Return on equity
-49.09%
ROIC
-53.87%
Beta
0.84
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$1.50M
Earnings per share
-$3.90
Free cash flow
-$213.66M
Net profit margin
-268385.71%
Gross margin
-56850.89%
EBITDA
-$255.42M
Revenue growth
-78.63%
Similar securities
This is not an investment recommendation
How to buy Celldex Therapeutics from India
Indian residents can buy Celldex Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Celldex Therapeutics and place an order
Find Celldex Therapeutics by name or by its ticker, CLDX, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Celldex Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Celldex Therapeutics position in USD and INR. Celldex Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Celldex Therapeutics from India
Trading and taxes when buying Celldex Therapeutics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneCelldex Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Celldex Therapeutics stock?
Yes. Celldex Therapeutics (CLDX) has been listed on NASDAQ since 1986, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Celldex Therapeutics share cost in rupees?
One Celldex Therapeutics share is $31.64 — about ₹3,039 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the Celldex Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Celldex Therapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of Celldex Therapeutics?
Yes. One Celldex Therapeutics share is $31.64, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Celldex Therapeutics.
How are gains on Celldex Therapeutics shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Celldex Therapeutics price. Paasa issues a capital-gains statement for your return.
Does Celldex Therapeutics pay a dividend?
No. Celldex Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Celldex Therapeutics from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Celldex Therapeutics shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Celldex Therapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Celldex Therapeutics holding, its cost and its closing value.
How do I sell Celldex Therapeutics and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.